secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001372514-24-000099
Event type: regulatory
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharma receives EU orphan designation for KIO-301 in inherited retinal dystrophies
--------------------------------------------------------------------------------

- EMA grants Orphan Medicinal Product Designation for KIO-301 in non-syndromic rod-dominant retinal dystrophies including retinitis pigmentosa.
- Provides at least 10 years of market exclusivity in Europe, reduced fees, centralized approval, and EMA scientific advice.
- KIO-301 already has US Orphan Drug Designation; Phase 2 ABACUS-2 trial expected to initiate later in 2024.
- KIO-301 is a small molecule photoswitch designed to restore light sensing in degenerated retinas, a non-gene therapy approach.
- Co-development and commercialization partner Théa Open Innovation covers ex-Asia territories.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000099/0001372514-24-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251424000099/kprx-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001372514-24-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer